ClinicalTrials.gg
CompletedNCT01588509Updated Mar 26, 2019Results posted

Transition From Alendronate to Romosozumab (AMG 785)

A Phase 1 interventional study of Romosozumab in Osteoporosis, sponsored by Amgen. Completed at 9 sites in United States. Open to female participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-03-26.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing romosozumab in Osteoporosis — 5 open to participants now, 8 under way, none of them phase 3. romosozumab · Osteoporosis.

Enrollment
13th of 20
60 · median 80
Started
2012
with 3 others
Phase 1
3 of 20
none open now
Registered
2nd of 20
by date
Lead sponsor
8 of 20
Amgen

Among the 20 studies testing romosozumab in Osteoporosis, this one is the 13th largest by enrollment, is one of 4 that started in 2012, is one of 3 in phase 1, and was the 2nd registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

5 of the 20 studies testing romosozumab in Osteoporosis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 55 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing romosozumab in Osteoporosis, or all of them as a file.
02

Study summary

The purpose of this study is to estimate the percent change from baseline in lumbar spine bone mineral density (BMD) following multiple-dose administrations of romosozumab in postmenopausal women with low BMD previously treated with alendronate.

03

Conditions studied

  • Osteoporosis

Browse trials for

Keywords

  • AMG 785, bone mineral density, alendronate
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women, defined as no vaginal bleeding or spotting for ≥ 12 months
  • Low bone mineral density at screening [defined by a bone mineral density (BMD) T-score ≤ -2.0 and ≥ -4.0 at the lumbar spine (L1 to L4; or BMD T-score of evaluable vertebrae), total hip, or femoral neck]
  • Currently taking alendronate (70 mg weekly or equivalent) exclusively for ≥ 1 year with verbal agreement that the subject has taken ≥ 80% of their doses with good tolerance

Exclusion criteria

Exclusion Criteria:

  • History of vertebral fracture, or fragility fracture of the wrist, humerus, hip or pelvis after age 50; or recent bone fracture within 6 months prior to screening
  • History of metabolic or bone disease such as Paget's disease, rheumatoid arthritis, osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia, and malabsorption syndrome
  • Vitamin D deficiency (defined as 25-OH-VitD levels \< 20 ng/mL)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Romosozumab 140 mg

    Participants received romosozumab 140 mg administered subcutaneously once a month for 3 months.

    Drug: Romosozumab

  • Experimental
    Romosozumab 210 mg

    Participants received romosozumab 210 mg administered subcutaneously once a month for 3 months.

    Drug: Romosozumab

Interventions

  • Administered by subcutaneous injection

    Also known as: AMG 785, EVENITY™

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine

    Bone mineral density was assessed by dual energy X-ray absorptiometry (DXA) scans of the lumbar spine (L1-L4) and analyzed by a central imaging lab.

    Time frame: Baseline and day 85

Secondary outcomes

  1. Percent Change From Baseline in Bone Mineral Density (BMD) at the Femoral Neck

    Bone mineral density was assessed by dual energy X-ray absorptiometry (DXA) scans and analyzed by a central imaging lab.

    Time frame: Baseline and day 85

  2. Percent Change From Baseline in Bone Mineral Density (BMD) at the Total Hip

    Bone mineral density was assessed by dual energy X-ray absorptiometry (DXA) scans and analyzed by a central imaging lab.

    Time frame: Baseline and day 85

  3. Percent Change From Baseline in Serum Type-1 Aminoterminal Propeptide (P1NP)

    Time frame: Baseline and days 4, 15, 29, 43, 57, 71, and 85

  4. Percent Change From Baseline in Serum C-telopeptide (sCTX)

    Time frame: Baseline and days 4, 15, 29, 43, 57, 71, and 85

  5. Number of Participants With Adverse Events

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events. A treatment-related adverse event (TRAE) was an adverse event assessed by the investigator as possibly related to the investigational product, indicated by a "yes" response to the question: Is there a reasonable possibility that the event may have been caused by the investigational product? A serious adverse event was defined as an adverse event that met at least 1 of the following serious criteria: * fatal, * life-threatening, * required in-patient hospitalization or prolongation of existing hospitalization, * resulted in persistent or significant disability/incapacity, * congenital anomaly/birth defect, and/or * other medically important serious event.

    Time frame: From first dose of study drug up to day 85

  6. Number of Participants Who Developed Anti-romosozumab Antibodies

    Two validated assays were used to detect the presence of anti-romosozumab antibodies. An electrochemiluminescent bridging immunoassay was used to detect binding antibodies (screening assay) and confirm antibodies (confirmatory assay) capable of binding romosozumab. Samples testing positive in the immunoassay were further tested in a competitive binding bioassay for neutralizing activity against romosozumab. If a sample was positive for binding antibodies and demonstrated neutralizing activity, the participant was defined as positive for neutralizing antibodies. Participants who developed anti-romosozumab antibodies were those with a negative result at baseline and a positive result at any time postbaseline.

    Time frame: Baseline and days 29, 57, and 85

  7. Mean Serum Concentration of Romosozumab

    Time frame: Days 4, 15, 29, 43, 57, 71 and 85

07

Results

Posted Mar 4, 2019

Participant flow

This study was conducted at 8 centers in the United States. The first participant enrolled on 30 March 2012 and the last participant enrolled on 21 August 2012.

Participant flow — Overall Study
MilestoneRomosozumab 140 mgRomosozumab 210 mg
Started3030
Received treatment3030
Completed2930
Not completed10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPercent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine

Bone mineral density was assessed by dual energy X-ray absorptiometry (DXA) scans of the lumbar spine (L1-L4) and analyzed by a central imaging lab.

Time frame:
Baseline and day 85
Reported as:
Mean · percent change
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine
percent changeRomosozumab 140 mgRomosozumab 210 mg
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine2.13 ± 0.642.08 ± 0.63
Statistical analysis
  • Romosozumab 140 mg · ANOVA · p = 0.002 · Percent change from baseline: 2.13 · 90% CI 1.05 to 3.20
  • Romosozumab 210 mg · ANOVA · p = 0.002 · Percent change from baseline: 2.08 · 90% CI 1.02 to 3.14
SecondaryPercent Change From Baseline in Bone Mineral Density (BMD) at the Femoral Neck

Bone mineral density was assessed by dual energy X-ray absorptiometry (DXA) scans and analyzed by a central imaging lab.

Time frame:
Baseline and day 85
Reported as:
Mean · percent change
Percent Change From Baseline in Bone Mineral Density (BMD) at the Femoral Neck
percent changeRomosozumab 140 mgRomosozumab 210 mg
Percent Change From Baseline in Bone Mineral Density (BMD) at the Femoral Neck2.06 ± 0.591.92 ± 0.58
Statistical analysis
  • Romosozumab 140 mg · ANOVA · p = <0.001 · Percent change from baseline: 2.06 · 90% CI 1.07 to 3.05
  • Romosozumab 210 mg · ANOVA · p = 0.002 · Percent change from baseline: 1.92 · 90% CI 0.95 to 2.89
SecondaryPercent Change From Baseline in Bone Mineral Density (BMD) at the Total Hip

Bone mineral density was assessed by dual energy X-ray absorptiometry (DXA) scans and analyzed by a central imaging lab.

Time frame:
Baseline and day 85
Reported as:
Mean · percent change
Percent Change From Baseline in Bone Mineral Density (BMD) at the Total Hip
percent changeRomosozumab 140 mgRomosozumab 210 mg
Percent Change From Baseline in Bone Mineral Density (BMD) at the Total Hip1.38 ± 0.341.40 ± 0.34
Statistical analysis
  • Romosozumab 140 mg · ANOVA · p = <0.001 · Percent change from baseline: 1.38 · 90% CI 0.81 to 1.95
  • Romosozumab 210 mg · ANOVA · p = <0.001 · Percent change from baseline: 1.40 · 90% CI 0.84 to 1.96
SecondaryPercent Change From Baseline in Serum Type-1 Aminoterminal Propeptide (P1NP)
Time frame:
Baseline and days 4, 15, 29, 43, 57, 71, and 85
Reported as:
Mean · percent change
Percent Change From Baseline in Serum Type-1 Aminoterminal Propeptide (P1NP)
percent changeRomosozumab 140 mgRomosozumab 210 mg
Day 422.1263 ± 3.385230.4935 ± 4.9950
Day 15140.9970 ± 15.1975218.4994 ± 22.6148
Day 29128.3936 ± 17.7834221.9954 ± 23.3718
Day 43164.1654 ± 17.7832251.0495 ± 23.4572
Day 5799.3682 ± 14.9155168.7689 ± 17.1565
Day 71127.4051 ± 14.8572205.2619 ± 23.5171
Day 8564.9103 ± 10.5005142.5601 ± 20.3233
SecondaryPercent Change From Baseline in Serum C-telopeptide (sCTX)
Time frame:
Baseline and days 4, 15, 29, 43, 57, 71, and 85
Reported as:
Mean · percent change
Percent Change From Baseline in Serum C-telopeptide (sCTX)
percent changeRomosozumab 140 mgRomosozumab 210 mg
Day 4-28.2149 ± 3.9352-14.8099 ± 4.6844
Day 15-28.9365 ± 4.6974-22.2800 ± 5.1854
Day 293.1008 ± 8.6448-1.8188 ± 7.4121
Day 433.4511 ± 8.991311.0131 ± 10.0244
Day 5725.7433 ± 8.744035.7697 ± 13.5346
Day 7128.4465 ± 11.734544.3802 ± 13.7159
Day 8554.0549 ± 14.214061.1734 ± 13.9874
SecondaryNumber of Participants With Adverse Events

An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events. A treatment-related adverse event (TRAE) was an adverse event assessed by the investigator as possibly related to the investigational product, indicated by a "yes" response to the question: Is there a reasonable possibility that the event may have been caused by the investigational product? A serious adverse event was defined as an adverse event that met at least 1 of the following serious criteria: * fatal, * life-threatening, * required in-patient hospitalization or prolongation of existing hospitalization, * resulted in persistent or significant disability/incapacity, * congenital anomaly/birth defect, and/or * other medically important serious event.

Time frame:
From first dose of study drug up to day 85
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsRomosozumab 140 mgRomosozumab 210 mg
All adverse events1415
Serious adverse events00
AE leading to discontinuation of study drug00
AE leading to discontinuation from study00
Fatal adverse events00
Treatment-related adverse events34
Treatment-related serious adverse events00
TRAE leading to discontinuation of study drug00
TRAE leading to discontinuation from study00
Treatment-related fatal adverse events00
SecondaryNumber of Participants Who Developed Anti-romosozumab Antibodies

Two validated assays were used to detect the presence of anti-romosozumab antibodies. An electrochemiluminescent bridging immunoassay was used to detect binding antibodies (screening assay) and confirm antibodies (confirmatory assay) capable of binding romosozumab. Samples testing positive in the immunoassay were further tested in a competitive binding bioassay for neutralizing activity against romosozumab. If a sample was positive for binding antibodies and demonstrated neutralizing activity, the participant was defined as positive for neutralizing antibodies. Participants who developed anti-romosozumab antibodies were those with a negative result at baseline and a positive result at any time postbaseline.

Time frame:
Baseline and days 29, 57, and 85
Reported as:
Count of participants · Participants
Number of Participants Who Developed Anti-romosozumab Antibodies
ParticipantsRomosozumab 140 mgRomosozumab 210 mg
Binding antibody positive22
Neutralizing antibody positive00
SecondaryMean Serum Concentration of Romosozumab
Time frame:
Days 4, 15, 29, 43, 57, 71 and 85
Reported as:
Mean · ng/mL
Mean Serum Concentration of Romosozumab
ng/mLRomosozumab 140 mgRomosozumab 210 mg
Day 415000 ± 635023200 ± 9730
Day 1510500 ± 354018500 ± 6640
Day 293890 ± 20008200 ± 4470
Day 4314300 ± 428022800 ± 9390
Day 575490 ± 260010700 ± 6380
Day 7113700 ± 500022700 ± 10500
Day 855350 ± 319011600 ± 6850

Adverse events

Collected over From first dose of study drug up to day 85. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Romosozumab 140 mg—0/30 (0%)11/30 (36.7%)
Romosozumab 210 mg—0/30 (0%)6/30 (20%)
Most frequent other events
Most frequent other events
EventRomosozumab 140 mgRomosozumab 210 mg
FatigueGeneral disorders3/300/30
ArthralgiaMusculoskeletal and connective tissue disorders3/301/30
Injection site reactionGeneral disorders0/302/30
Oedema peripheralGeneral disorders0/302/30
NasopharyngitisInfections and infestations2/301/30
Upper respiratory tract infectionInfections and infestations1/302/30
ContusionInjury, poisoning and procedural complications2/301/30
Muscle spasmsMusculoskeletal and connective tissue disorders2/300/30
Musculoskeletal painMusculoskeletal and connective tissue disorders2/300/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Romosozumab 140 mgRomosozumab 210 mgTotal
Mean65.6 ± 7.566.7 ± 8.366.1 ± 7.8
Age, Customized
Age, Customized(Participants)Romosozumab 140 mgRomosozumab 210 mgTotal
< 65 years141529
≥ 65 years161531
Sex: Female, Male
Sex: Female, Male(Participants)Romosozumab 140 mgRomosozumab 210 mgTotal
Female303060
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Romosozumab 140 mgRomosozumab 210 mgTotal
Hispanic or Latino121426
Not Hispanic or Latino181634
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Romosozumab 140 mgRomosozumab 210 mgTotal
American Indian or Alaska Native000
Asian527
Black (or African American)000
Native Hawaiian or Other Pacific Islander022
Other011
White252550
08

Study locations

9 sites
  • Research Site
    Tucson, Arizona 85711, United States
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    Gainesville, Georgia 30501, United States
  • Research Site
    Honolulu, Hawaii 96813, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Albuquerque, New Mexico 87106, United States
  • Research Site
    West Haverstraw, New York 10993, United States
  • Research Site
    Wyomissing, Pennsylvania 19610, United States
  • Research Site
    Seattle, Washington 98144, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in Nov 2012, 7 months.

Results were first posted in Mar 2019, 6 years 3 months after primary completion.

Of 30 phase 1 interventional studies under Osteoporosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 22. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2012
First posted
May 1, 2012
StartActual
Mar 30, 2012
Primary completionActual
Nov 21, 2012
CompletionActual
Nov 21, 2012
Results first posted
Mar 4, 2019
Last update
Mar 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01588509
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 1, 2012
Start date
Mar 30, 2012
Primary completion
Nov 21, 2012
Completion
Nov 21, 2012
Results posted
Mar 4, 2019
Last update
Mar 26, 2019

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion